Methylene blue: Difference between revisions
Neil.m.young (talk | contribs) (Reverted edits by Neil.m.young (talk) to last revision by Kxl328) |
ClaireLewis (talk | contribs) |
||
| Line 54: | Line 54: | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:Toxicology]] | |||
Revision as of 23:21, 22 September 2019
Administration
- Type: Antidote, Vasopressors
- Routes of Administration: IV
Adult Dosing
- Acquired methemoglobinemia: 1 mg/kg IV over 5-30min, may repeat in 1h with up to 1 mg/kg IV if methemoglobin level still >30% or symptoms persist
- Drug-induced methemoglobinemia: 1-2 mg/kg IV slowly over several minutes
- See vasopressors
- For hypotension refractory to catecholamine pressors
- Consider after catecholamine, vasopressin, and mineralocorticoid refractive shock
Pediatric Dosing
- Same as weight-based adult dosing
Special Populations
- Pregnancy Rating: Fetal risk has been demonstrated
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing: no adjustment
- Hepatic dosing: no adjustment
Contraindications
- Allergy to class/drug
- G6PD deficiency
- ARDS
- Pulmonary hypertension
Adverse Reactions
Serious[1]
- Hemolytic anemia
- Syncope
- Serotonin syndrome
- Paradoxical methemoglobinemia at doses > 4 mg/kg/hr or per bolus
- Pulmonary vasoconstriction at 3-4 mg/kg/hr or per bolus
Common
- Skin discoloration, urine discoloration, hyperhidrosis
- Nausea, abnormal taste
- Limb pain
- Dizziness, headache
Pharmacology
- Half-life: 24h
- Metabolism: Hepatic
- Excretion: Mostly renal
Mechanism of Action
- Promotes non-enzymatic redox conversion of methemoglobin to hemoglobin
Comments
See Also
References
- ↑ Pasin L et al. Methylene blue as a vasopressor: a meta-analysis of randomised trials. Crit Care Resusc. 2013 Mar;15(1):42-8.
